Real word evidence on rituximab utilization: Combining administrative and hospital-pharmacy data.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
    • Publication Information:
      Original Publication: San Francisco, CA : Public Library of Science
    • Subject Terms:
      Antineoplastic Agents, Immunological/*administration & dosage ; Drug Utilization/*statistics & numerical data ; Infections/*epidemiology ; Leukemia, Lymphocytic, Chronic, B-Cell/*drug therapy ; Lymphoma, Non-Hodgkin/*drug therapy ; Rituximab/*administration & dosage; Administration, Intravenous ; Administrative Claims, Healthcare/statistics & numerical data ; Adolescent ; Adult ; Aged ; Antineoplastic Agents, Immunological/adverse effects ; Databases, Factual/statistics & numerical data ; Female ; Follow-Up Studies ; Humans ; Infections/chemically induced ; Infections/immunology ; Italy/epidemiology ; Kaplan-Meier Estimate ; Leukemia, Lymphocytic, Chronic, B-Cell/immunology ; Leukemia, Lymphocytic, Chronic, B-Cell/mortality ; Longitudinal Studies ; Lymphoma, Non-Hodgkin/immunology ; Lymphoma, Non-Hodgkin/mortality ; Male ; Middle Aged ; Pharmacy Service, Hospital/statistics & numerical data ; Retrospective Studies ; Rituximab/adverse effects ; Time Factors ; Treatment Outcome ; Young Adult
    • Abstract:
      Purpose: To describe patterns of utilization, survival and infectious events in patients treated with rituximab at the University Hospital of Siena (UHS) to explore the feasibility of combining routinely collected administrative and hospital-pharmacy data for examining the real-world use of intravenous antineoplastic drugs.
      Methods: A retrospective, longitudinal cohort study was conducted using data from the Hospital Pharmacy of Siena (HPS) and the Regional Administrative Database of Tuscany (RAD). Patients aged ≥18 years with ≥1 rituximab administration recorded between January 2012 and June 2016 were identified in the HPS database. Anonymized patient-level data were linked to RAD. Rituximab utilization during the first year of treatment was described using HPS. Hospital diagnoses of adverse infectious events that occurred during the first year of follow-up and four-year survival were observed using RAD.
      Results: A total of 311 new users of rituximab were identified: 264 patients received rituximab for non-Hodgkin's lymphoma (NHL) and 47 were treated for chronic lymphocytic leukemia (CLL). Among new users with one complete year of follow-up (n = 203) over 95% received rituximab as the first-line treatment, and approximately 70% of them received 5-8 doses. No patient in the CLL group received >8 administrations. Four-year survival was approximately 70% in both CLL and NHL patients. Sepsis was the most frequent infectious event observed (5.1%).
      Conclusion: HPS and RAD provided complementary information on rituximab utilization, demonstrating their potential for future pharmacoepidemiological studies on antineoplastic medications administered in the Italian hospital setting. Overall, this general description of the real-world utilization of rituximab in patients treated for NHL and CLL at UHS was in line with treatment guidelines and current knowledge on the rituximab safety profile.
      Competing Interests: The authors have declared that no competing interests exist.
    • References:
      Blood. 2005 Dec 1;106(12):3725-32. (PMID: 16123223)
      Int J Infect Dis. 2011 Jan;15(1):e2-16. (PMID: 21074471)
      Clin Lymphoma Myeloma Leuk. 2014 Aug;14(4):277-83. (PMID: 24679633)
      Eur J Clin Pharmacol. 2018 May;74(5):637-643. (PMID: 29383397)
      Arch Med Res. 2015 Aug;46(6):454-61. (PMID: 26235285)
      Hepatology. 2015 Feb;61(2):703-11. (PMID: 25412906)
      J Hematol Oncol. 2016 Mar 22;9:28. (PMID: 27000264)
      Pharmacoepidemiol Drug Saf. 2017 Aug;26(8):890-899. (PMID: 28397352)
      J Pediatr. 2013 Jun;162(6):1252-8, 1258.e1. (PMID: 23269206)
      J Clin Oncol. 2016 Feb 10;34(5):495-500. (PMID: 26712227)
      Eur J Cancer Care (Engl). 2004 Jul;13(3):279-87. (PMID: 15196232)
      Joint Bone Spine. 2012 Jul;79(4):365-9. (PMID: 22285615)
      Blood Cancer J. 2016 Nov 11;6(11):e499. (PMID: 27834937)
      Drug Saf. 2019 Mar;42(3):347-363. (PMID: 30269245)
      Lancet. 2011 Jan 1;377(9759):42-51. (PMID: 21176949)
      Blood. 2012 Mar 29;119(13):3184-5. (PMID: 22461474)
      Ann Hematol. 2005 Jan;84(1):1-12. (PMID: 15480663)
      Drugs Aging. 2018 Dec;35(12):1099-1108. (PMID: 30361806)
      Lancet Oncol. 2006 May;7(5):379-91. (PMID: 16648042)
      Ann Oncol. 2015 Sep;26 Suppl 5:v78-84. (PMID: 26314781)
      Ann Oncol. 2015 Sep;26 Suppl 5:v116-25. (PMID: 26314773)
      Crit Care. 2012 Aug 31;16(4):231. (PMID: 22967460)
    • Accession Number:
      0 (Antineoplastic Agents, Immunological)
      4F4X42SYQ6 (Rituximab)
    • Publication Date:
      Date Created: 20200313 Date Completed: 20200617 Latest Revision: 20200617
    • Publication Date:
      20240105
    • Accession Number:
      PMC7067445
    • Accession Number:
      10.1371/journal.pone.0229973
    • Accession Number:
      32163477